Ask how to use Cerebrolysin and you will get answers about intramuscular shots, forum dosing charts, and cycle lengths borrowed from other research chemicals. None of that comes from a trial. Every randomized study of Cerebrolysin that exists, in stroke, in vascular dementia, or in traumatic brain injury, used one route and a narrow set of durations: a slow intravenous infusion, run daily for somewhere between 10 days and several months, in a hospital or clinic. That is the only “how to use” the evidence supports, and even that protocol carries a mixed, sometimes unflattering verdict from the people who have re-analyzed it most carefully.
What the stroke trials found, and what they didn’t
Cerebrolysin’s biggest and most cited human evidence comes from acute ischemic stroke, and the headline trial is a case study in a confirmatory endpoint that missed.
- CASTA randomized 1,070 patients across Asia to 30 mL of intravenous Cerebrolysin daily, or saline placebo, for 10 days on top of aspirin. The confirmatory primary endpoint, a combined test of the modified Rankin Scale, the Barthel Index, and the NIHSS at 90 days, showed no significant difference between groups. A post hoc subgroup of patients with more severe strokes (NIHSS above 12) trended favorably, but the authors themselves called that a trend requiring confirmation.[1]
1,070 patients in CASTA, the largest Cerebrolysin stroke trial, which missed its primary endpoint PMID 22282884
- CARS took a narrower, more promising angle: patients with arm paresis after stroke got 30 mL of Cerebrolysin daily for 21 days alongside rehabilitation, versus placebo plus the same rehab. The Action Research Arm Test score at day 90 showed a large effect favoring Cerebrolysin (Mann-Whitney 0.71, 95% CI 0.63 to 0.79, P<0.0001).[2] That is a real signal, but Muresanu and colleagues described their own trial as exploratory and said the finding needed replication in a larger study. Nobody has published that replication.
Then there is the most recent Cochrane review, which pooled 7 RCTs and 1,773 participants and landed somewhere less generous than either trial alone. It found moderate-certainty evidence that Cerebrolysin probably has no effect on all-cause death (risk ratio 0.96), and a statistically significant increase in non-fatal serious adverse events versus placebo (risk ratio 2.39, 95% CI 1.10 to 5.23), an effect that got worse in the specific 30 mL-for-10-days schedule used in CASTA and similar trials (risk ratio 2.87).[3] It also flagged something easy to miss: none of the included trials reported on death or dependency at all, the outcome that matters most to a stroke patient.
2.39 relative risk of a non-fatal serious adverse event with Cerebrolysin versus placebo, per the 2023 Cochrane update PMID 37818733
Bottom line on stroke: The most recent systematic review found no survival benefit and a higher rate of serious adverse events than placebo. That risk profile gets worse the more carefully you look at it.
Where the dementia evidence stands
Dementia is the other major indication, and here the picture tilts more favorably, at least on paper.
A randomized, placebo-controlled trial in 242 patients with vascular dementia gave 20 mL of intravenous Cerebrolysin once daily across two treatment cycles over 24 weeks. The ADAS-cog score improved 10.6 points versus 4.4 points for placebo (P<.0001), and the global clinical impression scale moved the same direction.[4] A separate meta-analysis of six randomized, placebo-controlled trials of 30 mL/day Cerebrolysin in mild-to-moderate Alzheimer’s disease found significant improvement in cognition at four weeks and in global clinical change at four weeks and six months, compared with placebo.[5]
Worth saying plainly: every one of these trials, stroke and dementia alike, used the same comparator design. The alteplase-plus-Cerebrolysin stroke trial, like CASTA and CARS, measured the drug against a placebo of equal-volume saline.[6] Nobody has ever tested Cerebrolysin against an active cognitive-enhancing drug. The entire evidence base answers “better than nothing,” never “better than the alternative.”
Cerebrolysin is a mixture of peptide fragments, and that complicates dosing
Here is where “how to use” gets structurally strange. Cerebrolysin is not a single defined peptide with a known half-life, the way semaglutide or BPC-157 is. Comparative analyses of brain-hydrolysate neurotrophic drugs describe it as standardized for elemental composition and containing a mix of active peptide fragments, including nerve growth factor, enkephalin, orexin, and galanin fragments, rather than one active compound.[7]

Cerebrolysin is dozens of peptide fragments sharing one bag, each with its own possible dose-response curve.
That matters because standard single-compound pharmacokinetics, the kind that lets you say “250 mcg once daily” with confidence, doesn’t map cleanly onto a product that is dozens of different fragments at once. Each fragment could have its own absorption and clearance profile; nobody has published a human pharmacokinetic study that tracks them individually.
The proposed neurotrophic and anti-apoptotic mechanisms layer on more uncertainty. In a rat middle-cerebral-artery occlusion model, researchers measured Cerebrolysin’s effects on brain-derived neurotrophic factor, TNF-alpha, and apoptosis markers including Fas, Bax, and caspase-3 by Western blot, alongside comparator drugs Mexidol and Cortexin.[8] That is rodent data from an injected peptide mixture, and rodent data is where the mechanism story currently stops. It has not been proven in the species that matters to the person asking “how do I use this.”
The dose and route every trial used
This is the part that answers the question in the title, and it is narrower than most forum threads assume.
What each randomized Cerebrolysin trial dosed
| Trial | Population | Dose | Duration |
|---|---|---|---|
| CASTA | Acute ischemic stroke, n=1,070 | 30 mL IV daily | 10 days |
| CARS | Stroke with arm paresis | 30 mL IV daily, plus rehab | 21 days |
| TBI pilot | Mild traumatic brain injury | 30 mL IV daily, 60-minute infusion | 5 days |
| Vascular dementia trial | Vascular dementia, n=242 | 20 mL IV daily, two cycles | 24 weeks |
| Alzheimer's dosing study | Mild-to-moderate Alzheimer's | 10, 30, or 60 mL IV | 4 weeks daily, then 8 weeks twice-weekly |
Every trial listed here administered the drug by intravenous infusion alone.
A randomized trial in mild traumatic brain injury gave Cerebrolysin as a once-daily intravenous infusion of 30 mL over a 60-minute period for five days, matched by equal-volume saline placebo.[9] Add that to CASTA, CARS, and the vascular dementia trial, and the pattern is total: every major randomized Cerebrolysin trial used intravenous infusion. None tested a subcutaneous injection, a nasal spray, or an oral capsule. Dementia trials followed a different rhythm than the stroke trials, daily infusions five days a week for four weeks, then twice-weekly infusions for an additional eight weeks, rather than the shorter continuous stroke courses.[10]
What nobody has tested: Not one controlled trial has given Cerebrolysin as a subcutaneous shot, a nasal spray, or a capsule. A fixed, self-administered intramuscular schedule of the kind described in online nootropic threads has never been studied at all. If you are using it that way, you are not replicating a protocol. You are inventing one.
Cerebrolysin isn’t unusual in facing this gap between trial route and forum route. Insulin spent decades as an effective peptide hormone that only worked by injection, until formulation chemistry eventually caught up with an oral version. Sermorelin faces a similar split today: its human data comes from injections, while oral capsules sold online skip the step that was tested. Because Cerebrolysin is a mixture of many peptide fragments rather than one defined molecule, standard single-compound pharmacokinetic analysis doesn’t even apply to it cleanly, let alone extend to an untested route.
What the safety data covers, and what it doesn’t
A meta-analysis pooling six randomized controlled trials in 1,649 acute ischemic stroke patients found no significant difference between Cerebrolysin and placebo in adverse events, serious adverse events, or mortality, and concluded that routine administration could not be supported by the available trial evidence for functional recovery.[11] That sits in tension with the Cochrane review’s SAE signal above, which is itself a sign of how unsettled this evidence base is: different pooling choices produce different verdicts on the same drug.
Two claims circulate constantly around Cerebrolysin that this search could not verify against a citable source:
- Seizure risk in people with epilepsy. No study in this review reported seizure activity as an adverse event or discussed an epilepsy contraindication directly.
- Allergic or anaphylactoid reactions. No case report specific to Cerebrolysin surfaced. Every candidate source was a general anaphylaxis guideline unrelated to this drug.
Both claims may turn out to be accurate. Product labeling in the countries where Cerebrolysin is approved may well say exactly this. But “a common warning on peptide forums” is not the same as “a documented finding in the trial literature,” and this article draws that line rather than smoothing over it. None of the controlled trials monitored for interactions with other nootropic compounds either, so combining Cerebrolysin with other peptides sold online carries an absence of safety data rather than a reassurance of it.
Where Cerebrolysin sits against citicoline and Semax
If the goal is stroke recovery with a route you can administer outside a hospital, Cerebrolysin is the wrong peptide to reach for.
Oral citicoline has been tested in a pooled analysis of four randomized, placebo-controlled stroke trials using doses of 500 to 2,000 mg, with a modest but statistically significant recovery benefit over placebo (25.2% recovery versus 20.2%, odds ratio 1.33).[12] That is a smaller effect than CARS reported for Cerebrolysin, but it comes in a tablet. Semax, a Russian-developed peptide also studied in ischemic stroke trials, has been dosed in micrograms per day over defined treatment courses rather than Cerebrolysin’s milliliter-volume IV infusion.[13] KPV runs into the same mismatch between the tested route and the sold route: a peptide with a real mechanism story, administered by researchers one way and by buyers another.
Measured against alternatives dosed orally or in smaller, non-infusion formats, Cerebrolysin’s requirement for infusion access makes it the least practical option of the three for anyone outside a clinical setting. That is not a minor inconvenience. It is the difference between a treatment you can replicate and one you cannot.
What would change this picture
A large confirmatory trial replicating the CARS motor-recovery finding, powered specifically for that endpoint, would matter more than any other single study that could be run right now. CARS is Cerebrolysin’s best positive signal, and it is also the one result the trial’s own authors said wasn’t big enough to stand on its own.
Until somebody tests a non-infusion route in a controlled trial, the honest answer to “how do I use Cerebrolysin” for anyone outside a hospital is that no studied protocol exists for the way it is typically self-administered. Not a safer dose. Not a shorter cycle. No protocol at all.
The honest answer: Cerebrolysin’s tested use is a hospital IV drip for 10 to 21 days under medical supervision, with a mixed efficacy record and a Cochrane-flagged increase in serious adverse events. Everything else circulating about how to use it is improvisation.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
- Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial.. Stroke, 2012.
- Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.. Stroke, 2016.
- Cerebrolysin for acute ischaemic stroke.. The Cochrane database of systematic reviews, 2023.
- Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2011.
- Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.. Dementia and geriatric cognitive disorders, 2015.
- A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke.. International journal of stroke : official journal of the International Stroke Society, 2013.
- [Comparative studies of neurotrophic drugs based on brain hydrolysates].. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2019.
- [The effect of neuroprotectors on the level of BDNF, tumor necrosis factor alpha and apoptosis markers, and in acute cerebrovascular accidents].. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2026.
- Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study.. British journal of neurosurgery, 2013.
- A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.. European journal of neurology, 2006.
- Cerebrolysin for functional recovery in patients with acute ischemic stroke: a meta-analysis of randomized controlled trials.. Drug design, development and therapy, 2017.
- Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials.. Stroke, 2002.
- [The efficacy of semax in the tretament of patients at different stages of ischemic stroke].. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2018.



